-transparent.png){kind=logo}
In a field trial 181 high risk persons of both sexes between ages of 2--71 years were prophylactically vaccinated against rabies with the beta-propiolactone inactivated rabies-vaccine (hdc) mrc-5. 1 ml of vaccine was administered intramuscularly on days 0, 7 and 21. Serum samples were collected on days 0, 7, 21 and 35. Neutralizing antibody titers against the rabies virus were determined in the rapid fluorescent focus inhibition test, 7 days after the first injection measurable titers of antibodies were found in all sera with one exception. On day 21 all persons showed a 100% seroconversion with a mean titer of 1:1000 (8,3 IU/ml). On day 35 the final mean titer measured 1:2400 (20 IU/ml). Major side effects during the prophylactic vaccination were not observed.
J H Cox, and
W Klietmann, and
L G Schneider
December 1978,
Deutsche medizinische Wochenschrift (1946),
J H Cox, and
W Klietmann, and
L G Schneider
January 1978,
Developments in biological standardization,
J H Cox, and
W Klietmann, and
L G Schneider
September 1984,
Lijecnicki vjesnik,
J H Cox, and
W Klietmann, and
L G Schneider
November 1979,
Medizinische Klinik,
J H Cox, and
W Klietmann, and
L G Schneider
March 1984,
The Journal of communicable diseases,
J H Cox, and
W Klietmann, and
L G Schneider
April 1995,
Vaccine,
J H Cox, and
W Klietmann, and
L G Schneider
January 1982,
Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Bacteriologia, virusologia, parazitologia, epidemiologia,
J H Cox, and
W Klietmann, and
L G Schneider
June 1996,
Presse medicale (Paris, France : 1983),
J H Cox, and
W Klietmann, and
L G Schneider
January 1997,
The Journal of emergency medicine,
J H Cox, and
W Klietmann, and
L G Schneider
January 1978,
Zentralblatt fur Chirurgie,
